BUDGET IMPACT ANALYSIS OF GALCANEZUMAB-GNLM FOR THE PREVENTIVE TREATMENT OF PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE IN THE UNITED STATES

被引：0
作者：
Foster, S. A. [1 ]
Milev, S. [2 ]
Hoog, M. [3 ]
Mason, O. [1 ]
Sardesai, A. [4 ]
Hasan, A. [1 ]
Marrone, C. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Evidera, San Francisco, CA USA
[3] Evidera, Bethesda, MD USA
[4] Evidera, St Laurent, PQ, Canada
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.1313
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND40
引用
收藏
页码：S277 / S277
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of different doses of subcutaneous galcanezumab in chronic and episodic migraine: A pooled analysis of 3651 patients
    Zaazouee, Mohamed Sayed
    Elsnhory, Ahmed
    Ebrahim, Rokaya Y.
    Al-araj, Ghaida'a
    Saad, Ahmed
    Zaki, Ibram
    Ali, Mustafa Hussein
    Fawy, Omar Khaled Fahmy
    Ahmed, Hadi F.
    Elshennawy, Mohamed
    Eleyan, Mohammed
    Alahmad, Ziad
    Hamra, Reem I. Abo
    AbuEl-Enien, Hazem
    Elromely, Rasha Abdo
    Elshanbary, Alaa Ahmed
    NEUROLOGY, 2023, 100 (17)
  • [22] Immunogenicity findings from Phase 3 galcanezumab trials in patients with episodic or chronic migraine
    Martinez, James M.
    Garce, Sandra
    Anglin, Greg
    Hodsdon, Michael
    Kielbasa, William
    Moser, Brian A.
    Pearlman, Eric
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [23] A Real-World Perspective of Patients With Episodic Migraine or Chronic Migraine Prescribed AJOVY in the United States
    Cohen, J. M.
    Pandya, S.
    Krasenbaum, L. J.
    Thompson, S. F.
    Chen, C.
    Tangirala, K.
    HEADACHE, 2020, 60 : 5 - 6
  • [24] Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials
    Ruff, D. D.
    Ford, J. H.
    Tockhorn-Heidenreich, A.
    Stauffer, V. L.
    Govindan, S.
    Aurora, S. K.
    Terwindt, G. M.
    Goadsby, P. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 (04) : 609 - 618
  • [25] CHARACTERIZATION OF PREVENTIVE TREATMENT IN EPISODIC AND CHRONIC MIGRAINE PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALY
    Pegoraro, V
    Heiman, F.
    di Nola, L.
    Pulimeno, S.
    Burgio, L.
    VALUE IN HEALTH, 2018, 21 : S329 - S330
  • [26] Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine
    Martinez, James M.
    Hindiyeh, Nada
    Anglin, Greg
    Kalidas, Kavita
    Hodsdon, Michael E.
    Kielbasa, William
    Moser, Brian A.
    Pearlman, Eric M.
    Garces, Sandra
    CEPHALALGIA, 2020, 40 (09) : 978 - 989
  • [27] Immunogenicity Assessment from Phase 3 Galcanezumab Trials in Patients with Episodic or Chronic Migraine
    Martinez, James M.
    Hindiyeh, Nada
    Anglin, Greg
    Kalidas, Kavita
    Hodsdon, Michael E.
    Kielbasa, William
    Moser, Brian A.
    Pearlman, Eric
    Garces, Sandra
    NEUROLOGY, 2019, 92 (15)
  • [28] Healthcare Resource Use and Costs among Patients with Chronic and Episodic Migraine in the United States
    Stokes, Michael E.
    Varon, Sepideh F.
    Sullivan, Sean D.
    Blumenfeld, Andrew M.
    Lipton, Richard B.
    Goadsby, Peter J.
    Wilcox, Teresa K.
    NEUROLOGY, 2011, 76 (09) : A468 - A468
  • [29] Sustained response of galcanezumab in migraine prevention: Patient--level data from a post hoc analysis in patients with episodic or chronic migraine
    Tepper, Stewart J.
    Dong, Yan
    Vincent, Maurice
    Wietecha, Linda A.
    HEADACHE, 2023, 63 (10): : 1380 - 1390
  • [30] Effect of Galcanezumab on Severity of Headache and Associated Symptoms of Migraine in Phase 3 Trials in Patients with Episodic or Chronic Migraine
    Day, Kathleen A.
    Ament, Michael
    Stauffer, Virginia L.
    Skljarevski, Vladimir
    Rettiganti, Mallikarjuna
    Pearlman, Eric M.
    Aurora, Sheena K.
    NEUROLOGY, 2019, 92 (15)
12345